Solid Tumor: Clinical Trials

1,072 trials for Solid Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

364 completed, 247 recruiting, 173 unknown, 139 terminated. 754 Phase 1, 303 Phase 2, 68 Not applicable, 41 Early Phase 1, 7 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 1754Completed 284, Recruiting 168, Terminated 105, Unknown 104, Active not recruiting 54, Not yet recruiting 22, Withdrawn 12, Suspended 3, Enrolling by invitation 2
Phase 2303Recruiting 85, Completed 62, Terminated 52, Unknown 45, Active not recruiting 31, Not yet recruiting 15, Withdrawn 12, Enrolling by invitation 1
Not applicable68Completed 21, Unknown 18, Recruiting 16, Not yet recruiting 4, Active not recruiting 3, Withdrawn 3, Terminated 2, Suspended 1
Early Phase 141Unknown 16, Recruiting 14, Completed 4, Terminated 3, Not yet recruiting 2, Active not recruiting 1, Withdrawn 1
Phase 47Recruiting 3, Completed 2, Active not recruiting 1, Withdrawn 1
Phase 36Recruiting 3, Completed 2, Unknown 1

Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276
4SCAR-276 - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute1002027-06-012026-11-02
A Phase 1/2 Trial Of Larotrectinib And Pembrolizumab In Patients With Solid Tumors Previously Treated With Immune Checkpoint Inhibitor Monotherapy
Larotrectinib, Pembrolizumab - Solid Tumor
Phase 1 / Phase 2Not yet recruitingM.D. Anderson Cancer Center222027-03-012026-09-28
Intratumoral Chlorine Dioxide Injection in Advanced Solid Tumors
Chlorine Dioxide Injection 2% - Solid Tumor, Neoplasms
Phase 1Not yet recruitingSunGlow Innovations LLC502027-03-012026-11-02
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults
Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi
Phase 2Not yet recruitingNational Cancer Institute (NCI)152027-01-042026-10-29
GD2/PSMA Bi-specific CAR-T Cell Therapy
bi-4SCAR GD2/PSMA T cells - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute602026-12-312026-11-02
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
4SCAR-GD2 - Solid Tumor
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute102026-12-312026-10-30
An Investigational Study of BON-106 in Adults With Advanced or Metastatic Solid Tumors
BON-106 - Solid Tumor, Advanced Solid Tumor
Phase 1Not yet recruitingBeOne Medicines962026-12-012026-10-26
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Homogeneous External-Beam Radiotherapy, 20 Gy in Five Fractions, Homogeneous External-Beam Radiotherapy, 25 Gy in Five Fractions, LATTICE Radiotherapy, 20 Gy With a Simultaneous Integrated Boost to 66.7 Gy in Five Fractions - Solid Tumor
Not applicableNot yet recruitingAffidea Nu-med Center of Oncological DIagnostics and Therapy4262026-12-012026-11-02
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
[225Ac]Ac-FL-261 - Solid Tumor, NSCLC
Phase 1 / Phase 2RecruitingFull-Life Technologies UK Limited2082026-12-012026-11-16
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Natural history study of individuals with very rare tumors - Very Rare Tumors, Very Rare Cancers
RecruitingNational Cancer Institute (NCI)40002026-11-242026-11-19
A Phase Ib/II Study of BM230 in Combination With PD-1 Inhibitor for HER2-related Advanced Solid Tumors
BM230 & PD-1 inhibitor - Solid Tumor
Phase 1 / Phase 2Not yet recruitingSuzhou Biomissile Pharmaceuticals Co., Ltd.902026-11-012026-10-09
Validation of the G8 Screening Tool for Prognostic Assessment of Frailty and Early Mortality in Elderly Individuals With Cancer: Prospective Cohort Study in Brazil
Solid Tumor, Metastatic Solid Tumor
RecruitingLatin American Cooperative Oncology Group2502026-11-012026-11-13
A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics
HRS-8046 Tablet - Solid Tumor
Phase 1Not yet recruitingChengdu Suncadia Medicine Co., Ltd.1752026-11-012026-11-16
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
HRS-9308 Tablet - Solid Tumor
Phase 1 / Phase 2Not yet recruitingChengdu Suncadia Medicine Co., Ltd.1262026-11-012026-11-16
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Tagmokitug, Pasritamig - Solid Tumor
Phase 1 / Phase 2RecruitingCoherus Oncology, Inc.122026-11-012026-11-18
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
SHR-4595 for Injection - Solid Tumor
Phase 1RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2082026-10-202026-11-02
A Study of DS-3939a in Participants With Solid Tumors
DS-3939a, Pembrolizumab, Carboplatin - Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer
Phase 1 / Phase 2RecruitingDaiichi Sankyo4002026-10-132026-11-10
Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors
Proton P-SABR, Proton-Photon Hybrid P-SABR - Unresectable Malignant Neoplasm, Bulky Tumor
Not yet recruitingPeking University First Hospital602026-10-012026-09-14
Clinical Study of Tumor Polypeptide DC-CTL in the Treatment of Solid Tumors
Tumor polypeptide pool induced DC-CTL cell injection - Solid Tumor
Not applicableNot yet recruitingZhengzhou Revo-Gene Technology Co., LTD202026-10-012026-09-02
Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
ASKC189 - Solid Tumor, RAS Mutation
Phase 1Not yet recruitingJiangsu Aosaikang Pharmaceutical Co., Ltd.2002026-09-302026-09-23

Showing 20 of 1072. Sign in to see all of them.

Narrower conditions

Neoplasms (151)  ·  Neoplasm Metastasis (101)  ·  Carcinoma, Non-Small-Cell Lung (90)  ·  Colorectal Neoplasms (75)  ·  Breast Neoplasms (71)  ·  Lymphoma (57)  ·  Melanoma (56)  ·  Stomach Neoplasms (54)  ·  Ovarian Neoplasms (49)  ·  Pancreatic Neoplasms (48)  ·  Hematologic Neoplasms (46)  ·  Lung Neoplasms (37)  ·  Squamous Cell Carcinoma of Head and Neck (34)  ·  Endometrial Neoplasms (33)  ·  Carcinoma, Renal Cell (28)

Broader conditions

Neoplasms (417)  ·  Neoplasms by Site (379)  ·  Neoplasms by Histologic Type (250)  ·  Digestive System Diseases (165)  ·  Digestive System Neoplasms (161)  ·  Neoplasms, Glandular and Epithelial (142)  ·  Pathological Conditions, Signs and Symptoms (139)  ·  Respiratory Tract Diseases (136)  ·  Gastrointestinal Diseases (134)  ·  Skin and Connective Tissue Diseases (134)  ·  Lung Diseases (133)  ·  Skin Diseases (133)  ·  Hemic and Lymphatic Diseases (131)  ·  Pathologic Processes (128)  ·  Thoracic Neoplasms (127)

Interventions

pembrolizumab (66)  ·  Nivolumab (39)  ·  Paclitaxel (27)  ·  Cisplatin (24)  ·  Gemcitabine (23)  ·  Capecitabine (21)  ·  Docetaxel (21)  ·  Bevacizumab (18)  ·  Cyclophosphamide (18)  ·  Fluorouracil (18)  ·  Injections (18)  ·  atezolizumab (17)  ·  Carboplatin (14)  ·  Irinotecan (13)  ·  fludarabine (13)

Sponsors

Sichuan Baili Pharmaceutical Co., Ltd. (25)  ·  Eli Lilly and Company (20)  ·  Jiangsu HengRui Medicine Co., Ltd. (15)  ·  Memorial Sloan Kettering Cancer Center (14)  ·  M.D. Anderson Cancer Center (11)  ·  Merck Sharp & Dohme LLC (10)  ·  Vanderbilt-Ingram Cancer Center (10)  ·  Chinese PLA General Hospital (9)  ·  Dana-Farber Cancer Institute (9)  ·  Genentech, Inc. (9)  ·  Impact Therapeutics, Inc. (9)  ·  St. Jude Children's Research Hospital (9)  ·  Peking University Cancer Hospital & Institute (8)  ·  Athenex, Inc. (7)  ·  Hoffmann-La Roche (7)

Countries

United States (491)  ·  China (325)  ·  France (78)  ·  South Korea (70)  ·  Spain (69)  ·  Australia (61)  ·  Canada (47)  ·  United Kingdom (47)  ·  Japan (43)  ·  Belgium (30)  ·  Italy (30)  ·  Netherlands (30)  ·  Taiwan (27)  ·  Germany (23)  ·  Denmark (17)

Top investigators

David Cutler, MD (5)  ·  Jian Zhang (4)  ·  Anna Spreafico, MD (3)  ·  Barbara A. Murphy, MD (3)  ·  Chuanling Li (3)

Results publications

PMID 38172595, PMID 29505699, PMID 31401903, PMID 35101941, PMID 37082579, PMID 37592303, PMID 42109657, PMID 42413526, PMID 42636835, PMID 12637481, PMID 16575919, PMID 17244780, PMID 18463792, PMID 19139178, PMID 20305636, PMID 21601826, PMID 21739119, PMID 21810918, PMID 22382879, PMID 22415795, PMID 23615181, PMID 24173967, PMID 24349470, PMID 24477603, PMID 24523121, PMID 24819685, PMID 25086465, PMID 25287830, PMID 25380636, PMID 26095785, PMID 26172205, PMID 26222558, PMID 26390038, PMID 26600474, PMID 26808671, PMID 26836990, PMID 26942463, PMID 26966027, PMID 26984445, PMID 26984449, PMID 27000274, PMID 27053773, PMID 27138582, PMID 27157491, PMID 27240885, PMID 27247226, PMID 27565932, PMID 27627808, PMID 27646946, PMID 27871319

NIH funding

2023 (15), 2018 (10), 2019 (8), 2016 (7), 2015 (6), 2014 (5), 2017 (3), 2008 (2), 2025 (1), K08CA279500 (1), K12CA167540 (1), P01CA111412 (1), P30CA012197 (1), P30CA016059 (1), P30CA068485 (1)